Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of cancer therapies. Co.'s two primary product candidates are, revumenib (SNDX-5613), and axatilimab (SNDX-6352). Co. is developing SNDX-5613, a small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia, and acute myeloid leukemia, or AML, and NPM1 mutant AML. Co. is also developing SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1, in chronic graft-versus-host disease, as well as idiopathic pulmonary fibrosis. The SNDX YTD return is shown above.
The YTD Return on the SNDX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether SNDX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SNDX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|